U.S. markets close in 20 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.00+0.06 (+0.24%)
As of 3:40PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close24.94
Open24.99
Bid24.98 x 800
Ask25.01 x 900
Day's Range24.59 - 25.22
52 Week Range15.33 - 43.00
Volume246,884
Avg. Volume737,596
Market Cap1.668B
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-1.74
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
    GlobeNewswire

    Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

    SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat on Thursday, May 20, 2021 at 10:20 a.m. PT / 1:20 p.m. ET. A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. Kura is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com. Contacts Company:Pete De SpainVice President, Investor Relations &Corporate Communications(858) 500-8803pete@kuraoncology.com Investors:Robert H. UhlManaging DirectorWestwicke ICR(858) 356-5932robert.uhl@westwicke.com Media:Jason SparkManaging DirectorCanale Communications(619) 849-6005jason@canalecomm.com

  • Was The Smart Money Right About Piling Into Kura Oncology, Inc. (KURA)?
    Insider Monkey

    Was The Smart Money Right About Piling Into Kura Oncology, Inc. (KURA)?

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the fourth quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

  • Kura Oncology, Inc. (KURA) Q1 2021 Earnings Call Transcript
    Motley Fool

    Kura Oncology, Inc. (KURA) Q1 2021 Earnings Call Transcript

    KURA earnings call for the period ending March 31, 2021.